JP2014531442A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531442A5
JP2014531442A5 JP2014530369A JP2014530369A JP2014531442A5 JP 2014531442 A5 JP2014531442 A5 JP 2014531442A5 JP 2014530369 A JP2014530369 A JP 2014530369A JP 2014530369 A JP2014530369 A JP 2014530369A JP 2014531442 A5 JP2014531442 A5 JP 2014531442A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
polypeptide
coli
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014530369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531442A (ja
Filing date
Publication date
Priority claimed from GB201115906A external-priority patent/GB201115906D0/en
Priority claimed from GBGB1213251.0A external-priority patent/GB201213251D0/en
Application filed filed Critical
Priority claimed from PCT/IB2012/054825 external-priority patent/WO2013038385A2/en
Publication of JP2014531442A publication Critical patent/JP2014531442A/ja
Publication of JP2014531442A5 publication Critical patent/JP2014531442A5/ja
Pending legal-status Critical Current

Links

JP2014530369A 2011-09-14 2012-09-14 Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ Pending JP2014531442A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201115906A GB201115906D0 (en) 2011-09-14 2011-09-14 Escherichia coli vaccine combination
GB1115906.8 2011-09-14
GB1213251.0 2012-07-25
GBGB1213251.0A GB201213251D0 (en) 2012-07-25 2012-07-25 Escherichia coli vaccine combination
PCT/IB2012/054825 WO2013038385A2 (en) 2011-09-14 2012-09-14 Escherichia coli vaccine combination

Publications (2)

Publication Number Publication Date
JP2014531442A JP2014531442A (ja) 2014-11-27
JP2014531442A5 true JP2014531442A5 (enExample) 2015-10-15

Family

ID=47116137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530369A Pending JP2014531442A (ja) 2011-09-14 2012-09-14 Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ

Country Status (5)

Country Link
US (2) US9511130B2 (enExample)
EP (1) EP2755994A2 (enExample)
JP (1) JP2014531442A (enExample)
CN (1) CN103930436A (enExample)
WO (1) WO2013038385A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN109234418B (zh) * 2018-11-20 2021-08-13 湖南中净生物科技有限公司 一种鉴别猪肺炎支原体野毒株和疫苗株的引物、试剂盒和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CN1285753A (zh) 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
EP1053015A2 (en) 1998-02-12 2000-11-22 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
CA2441530A1 (en) 2001-03-19 2002-09-26 Iomai Corporation Transcutaneous immunostimulation
EP1383918A4 (en) 2001-04-03 2005-01-05 Biosynexus Inc ANIMAL MODEL FOR DARMPATHOGENE
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2005103073A2 (en) 2004-04-27 2005-11-03 Intercell Ag Td antigens
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
SI2464658T1 (sl) * 2009-07-16 2015-02-27 Novartis Ag Detoksificirani imunogeni escherichie coli
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins

Similar Documents

Publication Publication Date Title
JP2015517489A5 (enExample)
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
CN106456723B (zh) 采用精氨酸酶i调节免疫系统的方法和组合物
JP2016539946A5 (enExample)
JP2013534532A5 (enExample)
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
JP2015522576A5 (enExample)
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
Zhang et al. Tongue sole (Cynoglossus semilaevis) prothymosin alpha: cytokine-like activities associated with the intact protein and the C-terminal region that lead to antiviral immunity via Myd88-dependent and-independent pathways respectively
JP2012525128A5 (enExample)
US9169477B2 (en) Compositions and methods for immunization against bacteria expressing a carbapenemase
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2015500827A5 (enExample)
RU2012107993A (ru) Полипептиды porhyromonas gingivalis
JP2015505831A5 (enExample)
JP2018529661A5 (enExample)
CA2907395A1 (en) Improved methods of use for recombinant human secretoglobins
JP2009519025A5 (enExample)
Yue et al. Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis
US8741302B2 (en) Polypeptide derived from Enterococcus and its use for vaccination
JP2018509423A5 (enExample)
JP2022533096A5 (enExample)
JP2019526261A5 (enExample)